2 news items
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
HTGC
30 Apr 24
], with an objective response rate (ORR) of 71%, rapid and robust tumour reduction, a long duration of effect, significant improvements in functional ability, good
Analyst Ratings For Hercules Capital
HTGC
10 Apr 24
' their stance, it reflects their response to recent developments related to Hercules Capital. This information provides a snapshot of how analysts
- Prev
- 1
- Next